Arkolith/Insider Trading/ADIL/Form 4

Davidson Matt

Chief Development Officer, DirectorADIAL PHARMACEUTICALS, INC. (ADIL) · full profile →Form 4 · filed Jun 16, 2026
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
6
5 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 12, 2026Grant(A)232K—$0297K
Jun 11, 2026Grant(A)62K——62K
Jun 11, 2026Grant(A)3K——3K
Jun 11, 2026Grant(A)2K——2K
Jun 11, 2026Grant(A)101——2K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 12, 2026Grant(A)232K—$0232K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-26-069037) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML